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Background: Despite significant investments of federal and state dollars to transition patient 
medical records to an all-electronic system, a chasm still exists between health care quality and 
payment for it. A major reason for this gap is the difficulty in evaluating health care outcomes 
based on claims data. Since both payers and patients may not appreciate how illness complexity 
impacts treatment outcomes, it is difficult to determine fair provider compensation.
Objectives: Chronic kidney disease (CKD) typifies these problems and is often associated 
with comorbidities that impact cost, health, and work productivity. Thus, the objective of this 
study was to evaluate an illness complexity score (ICS) based on a linear regression of select 
blood values that might assist in predicting average monthly reimbursements in CKD patients. 
A second objective was to compare the results of this ICS prediction to results obtained by 
prediction of average monthly reimbursement using CKD stage. A third objective was to analyze 
the relationship between the change in ICS, estimated glomerular filtration rate (eGFR), and 
CKD stage over time to average monthly reimbursement.
Methods: We calculated parsimonious values for select variables associated with CKD patients 
and compared the ICS to ordinal staging of renal disease. Data from 177 de-identified patients 
over 13 months was collected, which included 15 blood chemistry observations along with 
complete claims data for all medical expenses. To test for the relationship between average 
blood chemistry values, stages of CKD, age, and average monthly reimbursement, we modeled 
an association through a linear regression function of age, eGFR, and the Z-scores calculated 
from average monthly values of phosphorus, parathyroid hormone, glucose, hemoglobin, 
bicarbonate, albumin, creatinine, blood urea nitrogen, potassium, calcium, sodium, alkaline 
phosphatase, alanine aminotransferase, and white blood cells.
Results: The results of our study demonstrated that the association between average ICS values 
throughout the entire study period predicted average monthly reimbursements with an R2 value 
of 0.41. Comparing that value to the association between the average CKD stage and average 
monthly reimbursement demonstrated an R2 value of 0.08. Thus, ICS offers five times greater 
sensitivity over CKD staging as a measure of illness complexity.
Conclusion: Sorting the patient population by changes in CKD stage or ICS over the entire 
study period revealed significant differences between the two scoring methods. Groups scored 
by ICS demonstrated greater sensitivity by capturing dysfunction in other organ systems and 
had a better association with reimbursement than groups scored by CKD staging.
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used in clinical practice.”1 In 1994, the Institute of Medicine 
  supported that view and added that “quality of care is the 
degree to which health services for individuals and popula-
tions increase the likelihood of desired health outcomes and 
are consistent with current professional knowledge.”2
However despite these expectations, along with federal 
and state investments to transition patient medical records 
to an all-electronic system, a chasm still exists between 
reporting health care quality and measuring payment for 
it. Petersen et al, in an extensive review of the literature, 
compared various methods to improve quality through 
pay-for-performance programs.3 Their analysis concluded 
that most financial incentives were focused on the delivery 
of prevention services rather than health outcomes. Other 
investigators reported that so-called pay-for-performance 
programs impact some patients negatively, particularly 
those with mental illness and chemical dependency.4–6 These 
conclusions support the analysis of Porter and Teisberg and 
others that American health care competes on delivery of the 
lowest procedure price rather than a value-based outcome for 
individual patients.7–9 It is this enigma of value vs price that 
challenges American health care. Determining value requires 
an appreciation of the relationship between illness severity, 
expected outcome, and cost.
Currently most payers address high cost and outcome 
by encouraging the delivery of preventive medical services, 
such as up-to-date immunizations, early diagnostic studies 
including mammography, colonoscopy, Pap smears, prostate-
specific-antigen testing, or education in healthy life styles.10,11 
Though these services are valuable, patients still develop 
chronic illnesses that require treatment or palliative care. 
Indeed, such conditions dominate health care budgets. In 
order to compensate providers fairly, it would be helpful to 
understand the level of illness severity in each patient prior to 
starting treatment. In this manner, both payers and providers 
can evaluate cost and treatment outcome among patients of 
comparable complexity.
Chronic kidney disease (CKD), which has five stages 
of severity based on a declining glomerular filtration rate 
(GFR), is typically evaluated and compensated according 
to disease stage. Yet patients within any single stage may 
demonstrate higher complexity due to comorbid factors 
such as hypertension, diabetes, osteopenia, and congestive 
heart failure among others. Unfortunately without a scale to 
grade illness complexity in individual patients, payers must 
rely on disease stage or capitation agreements based on 
assumed group complexity to aggregate cost and compen-
sate providers.12,13 Though pay-for-performance programs 
attempt to improve both care and cost, if illness complexity 
before treatment is unknown, then value-based outcomes 
also remain unknown.14–16
With the introduction of accountable care organiza-
tions in the United States, there is renewed focus to link 
provider compensation to quality outcomes through risk 
adjusted capitation agreements within a patient centered 
medical home. However, determining risk in populations 
challenged by social and geographic barriers is difficult and 
often compels providers to accept reimbursement based on 
healthier populations. The end result is generally lower care 
for underserved populations.
In a previous study, the authors reported on patients with 
CKD, many with multiple comorbidities, and demonstrated 
a relationship between blood chemistry values and high-cost 
hospitalization.17 In this study, an example population of CKD 
patients with multiple comorbid conditions was analyzed in 
order to explore the association between an illness complex-
ity score (ICS) based on routine blood chemistry values to 
reimbursement.
The objective of this study was to formulate an ICS 
based on a linear regression of select blood values that could 
predict average monthly reimbursements in CKD patients. 
A second objective was to analyze the association between 
reimbursement and CKD stage. A third objective was to com-
pare performance between these two methods for predicting 
average monthly reimbursement.
Method
samples analyzed
The data set analyzed included 1104 de-identified patients 
from a local managed care organization’s kidney disease 
registry who had received treatment from November 2007 
through November 2008. Patients without a calculated stage 
of kidney disease or a repeated estimated GFR (eGFR) 
that was at or below 60 mL/minute over a 3-month period 
were excluded (216 patients), since they may have repre-
sented acute renal disease, which was not the focus of this 
study. After exclusion, 888 CKD patients remained in the 
sample.
Variable definitions
A total of 18 blood tests were requested from the managed 
care organization for analysis by a consulting group of uni-
versity nephrologists. The choice of tests was made based 
on each variable’s perceived importance in monitoring the 
health of CKD patients. The 18 blood tests were: serum 
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hemoglobin, hemoglobin, hematocrit, bicarbonate, albumin, 
creatinine, blood urea nitrogen, potassium, calcium, sodium, 
alkaline phosphatase, alanine aminotransferase, bilirubin, 
white blood cells (leukocytes), and eGFR. The data set also 
included the complete financial profile for all medical claims 
that were paid for services for these patients over the same 
time period. These costs were also studied.
Since blood tests ordered by physicians showed marked 
variation in selection and repetition, the remaining pool of 
888 patients were filtered into a data set of 177 patients with 
no missing values for the following 15 tests that were repeated 
at least twice or more over the study period: phosphorus, para-
thyroid hormone, glucose, hemoglobin, bicarbonate, albumin, 
creatinine, blood urea nitrogen, potassium, calcium, sodium, 
alkaline phosphatase, alanine aminotransferase, white blood 
cells, and eGFR. The blood tests for all patients at all times 
were performed by the same laboratory. Thus, the units of 
measurement and normal range for each test were common 
to all observations.
Data for each patient was organized on a spreadsheet with 
columns labeled for patient identification, date of medical 
service, payments for all reimbursed medical services, CKD 
stage, and results of each blood test. Rows were grouped by 
patient identification and chronological dates for medical 
services. Since all 15 blood tests were not repeated on each 
date that a medical procedure was delivered, test results were 
carried forward to subsequent rows until replaced by a fresh 
test result. The average number of data rows for each patient 
was 13.1 with most patients having one or more tests repeated 
in eight of the 13 study period months.
Next, with the exception of age and eGFR, each blood 
test result was converted to a Z-score as follows: the midpoint 
of the normal range for each test was taken as the mean, and 
the range divided by four as the standard deviation for a non-
diseased normal population. Each lab test was standardized 
using this mean and standard deviation to obtain a Z-score 
for each variable for each patient. Next the Z-scores for each 
patient’s test results, along with their age, eGFR, and all 
reimbursements in each respective column were averaged 
by month.
A summary spreadsheet contained 177 lines for each 
patient’s average age, eGFR, average monthly reimburse-
ment, and average Z-scores for all tests over the entire study 
period. These averaged values for all variables were utilized 
in a linear regression equation to develop a predictor for 
average monthly reimbursement in each patient. Graphs and 
significance levels were calculated on these results. The same 
regression coefficients used in the preceding equation were 
also employed to calculate ICS for each patient on each date 
of service in order to analyze change.
The change in ICS from start to end of the study period 
was used to cohort the population into three outcome groups: 
better, same, or worse. Changes in CKD stage from beginning 
to end of the study period was calculated directly from the 
laboratory values at date of service.
statistical methods
To test for the relationship between average blood chemistry 
values, stages of CKD, age, and average monthly reimburse-
ment, we modeled that association through a linear regression 
function of age, eGFR, and the Z-scores calculated from 
average monthly values of phosphorus, parathyroid hormone, 
glucose, hemoglobin, bicarbonate, albumin, creatinine, 
blood urea nitrogen, potassium, calcium, sodium, alkaline 
phosphatase, alanine aminotransferase, and white blood cells. 
A backward selection strategy was then employed to derive 
a parsimonious model containing only significant predictors. 
At each step, the explanatory variable with the highest P 
value greater than 0.10 was deleted. If its deletion resulted 
in another variable that had been significant (P , 0.10) pre-
viously becoming nonsignificant, then the deleted variable 
was added back into the model and the variable with the next 
largest P value greater than 0.10 was deleted. These steps 
were repeated until only significant variables (P , 0.10) 
remained in the model.
These analyses produced a regression table for the final 
model with an estimated intercept and regression coefficients 
for each explanatory variable, along with calculated P val-
ues. Next employing the regression coefficients calculated 
for the most parsimonious variables, these coefficients 
were employed in a regression equation to calculate a linear 
predictor by multiplying each appropriate regression coef-
ficient with their respective averaged explanatory variable 
and summed. The results for each patient were plotted on a 
scatter plot of ICS vs the natural logarithm for each patient’s 
average monthly reimbursement.
Next, employing the regression coefficients calculated for 
the most parsimonious variables, an ICS was calculated for 
each patient on each date of service with no missing variables. 
As described previously, the regression coefficients used to 
calculate each ICS on each date of service for each patient 
were derived from the linear regression calculation for the 
entire population based on average Z-scores for each patient. 
The chronological change calculated in this way throughout 
the study period permitted analysis of the relationship of 
outcome result (ie, change in ICS) to reimbursement.International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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Next, the coefficients of the linear regression of the 
  average natural logarithm for monthly reimbursements on 
average CKD stage categories for each patient over the entire 
study period were estimated. In a manner similar to develop-
ing a simple linear predictor for multiple blood tests above, 
the regression coefficient for CKD stage was multiplied with 
each observed indicator variable for stage and summed with 
the estimated intercept to produce a predicted value of reim-
bursement based on stage. Subsequently, these values were 
plotted in a scatter plot against the average natural logarithm 
for monthly reimbursement.
Finally, in order to evaluate the relationship between 
outcome and reimbursement, the study pool was sorted by 
change in ICS and CKD stage from first to last observa-
tion month. Since ICS is a continuous variable and stage 
is ordinal with a wide range for each stage, the change in 
eGFR from first to last observation month was also evalu-
ated. Since patients scored by any measure could remain 
the same, improved, or worse, the pool was divided into 
three groups based on ending CKD stage, ending ICS, and 
ending eGFR. The average values for each patient’s starting 
and ending CKD stage, ICS, or eGFR were evaluated by a 
paired t-test, and the significance for the change in average 
reimbursement within each subset was evaluated by an 
ANOVA calculation. In order to illustrate the predictive 
power of ICS and CKD staging to average monthly reim-
bursement, the average ICS and CKD stages from start to 
end of the study period for each patient were plotted in line 
graphs and compared to a similar plot for the log of average 
payments. In addition, R2 values were calculated from the 
simple linear regressions.
Results
Table 1 displays the coefficients and P values from the regres-
sion of the average logarithm of monthly reimbursement 
on the full set of variables in the table. This regression was 
based on the sample of 177 patients with observations on all 
variables analyzed. The overall R2 value from the regression 
was 0.424 (P = 0.0005).
Although the overall P value for the association of these 
variables to average monthly cost was significant, as shown 
in Table 1, a number of variables had P values that were 
not significant. After a step-wise elimination of the least 
significant variable at each step, a parsimonious model that 
did not suffer from multicollinearity was obtained and is 
presented in Table 2. This parsimonious set of variables 
had an overall P value of 0.0005, with an R2 of 0.41 and an 
adjusted R2 of 0.37.
The association between the ICS derived from this model 
and the average logarithm for monthly reimbursement for 
all health care services for each patient is shown in the scat-
ter plot of Figure 1. The average ICS over the entire study 
period are displayed on the x-axis, and are derived from the 
intercept plus a linear predictor derived by the sum of the 
Z-scores for each test multiplied by its respective variable 
coefficient shown in Table 2. That is, the ICS was defined as 
the predicted value of the average logarithm of reimburse-
ment. The average logarithms for monthly reimbursements 
for all health care services are displayed on the y-axis.
Table 1 Calculated coefficients and P values from the regression 
of  the  average  logarithm  of  monthly  reimbursement  for  the 
variables listed in the first column
Variable coefficient P value
Constant -2.84
Age 0.01 0.10
stage CKD 1.24 0.03
PO4 0.15 0.04
PTh 0.00 0.33
glucose 0.01 0.57
hemoglobin -0.33 0.00
Bicarbonate -0.03 0.71
Albumin -0.28 0.00
Creatinine 0.03 0.01
BUN 0.01 0.55
Potassium -0.07 0.33
Calcium 0.08 0.25
sodium 0.06 0.53
Alk-P -0.01 0.92
ALT 0.31 0.00
WBC 0.17 0.00
egFR 0.08 0.00
Abbreviations: Alk-P, alkaline phosphatase; ALT, alanine aminotransferase; BUN, 
blood  urine  nitrogen;  CKD,  chronic  kidney  disease;  egFR,  estimated  glomerular 
filtration rate; PO4, phosphate; PTH, parathyroid hormone; WBC, white blood cells.
Table 2 Calculated variable coefficients and P values for the 
parsimonious model obtained after a step-wise elimination of the 
least significant variables previously shown in Table 1
Variable coefficient P value
Constant -2.86
Age 0.01 0.09
CKD stage 1.31 0.02
PO4 0.17 0.01
hemoglobin -0.31 0.00
Albumin -0.25 0.00
Creatinine 0.03 0.00
ALT 0.30 0.00
WBC 0.16 0.00
egFR 0.08 0.00
Abbreviations:  ALT,  alanine  aminotransferase;  CKD,  chronic  kidney  disease; 
eGFR, estimated glomerular filtration rate; WBC, white blood cells.International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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As shown in Figure 1, complexity scores ranged from 
4.45 to 8.45 (x-axis) and were associated with increasing 
average monthly reimbursements: 4.11 to 9.26 (US$61 
to US$10,509; y-axis). The R2 value for the relationship 
between ICS and the average natural logarithm for monthly 
reimbursement for all health care services is 0.41.
Figure 2 in contrast is the scatter plot for the same CKD 
population, but sorted by average CKD stage for each 
patient over the study period. The average values for CKD 
stages are based on a calculated eGFR (Modification of Diet 
in Renal Disease 4) and weighted by their regression coef-
ficients which are displayed on the x-axis, while the average 
natural logarithm for monthly reimbursement for all health 
care services is shown on the y-axis.
The variation in average monthly dollars for all four 
CKD stages shown in Figure 2 varies from 4.11 to 9.26 
(US$61 to US$10,509). Interestingly, the widest range of 
  reimbursements was seen in the vertically aggregated dia-
monds seen at x-axis = 6.27 which is associated with CKD 
stage 3B. The linear regression for the association between 
average stage of CKD and average monthly reimbursement 
had an R2 value of 0.083 with an adjusted R2 of 0.078.
In order to compare the performance between average 
ICS and average CKD stage at predicting average natural 
logarithm for monthly reimbursement in each patient, the 
two patient pools were rank ordered by reimbursement 
amount from smallest to largest and plotted by line graphs 
as shown in Figures 3 and 4. Figure 3 is the line graph for 
177 patients displaying the relationship between ICS and the 
average natural logarithm for total monthly reimbursements. 
The irregular red line depicts ICS values (y-axis) for each 
patient displayed on the x-axis. The green slightly sigmoid-
shaped line illustrates the values for the natural logarithm 
of average monthly reimbursements for each patient (also 
on the y-axis scale). The range of these scores was from an 
ICS value of 5.6 to 7.7. As suggested by the R2 value of 0.41, 
there is correlation of the predicted ICS values to average 
monthly reimbursement in the midrange of the line graphs 
with a symmetrical divergence of ICS values at both the 
upper and lower regions of the graph.
In contrast, Figure 4 demonstrates a line graph compar-
ing average CKD stage to the average natural logarithm for 
monthly reimbursements in 177 patients. The linear trend line 
for the beta-weighted average stages of CKD ranged from a 
value of 6.2 to 6.9 with an R2 value of 0.083. The small cor-
relation of weighted CKD stage values with the line plot for 
average reimbursement confirms the predicted relationship 
by a wide divergence of the stage predicted values from the 
average monthly reimbursements.
In order to evaluate changes observed in ICS and CKD 
stage over the entire study period and to correlate those 
changes to reimbursement, the patient pool was sorted by 
change in both ICS and CKD stage from first to last obser-
vation and compared to their respective average monthly 
reimbursements. Since ICS is a continuous variable, while 
CKD stage is ordinal with a wide range of eGFR values 
in each stage, the patient pool was also sorted by change 
in eGFR values from start to end. The results of this pool 
segregation are displayed in Table 3 which lists the natural 
logarithm values for average monthly reimbursement for 
those patients who ended the study period with the same, 
better, or worse ending eGFR, ICS, or CKD stage. The first 
full row in Table 3 displays the number of patients with the 
same, better, or worse ending values for each scoring method. 
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Figure 1 scatter plot of illness complexity score (x-axis) derived as the predicted 
value  from  the  linear  regression  for  age,  chronic  kidney  disease  stage,  serum 
phosphorus, hemoglobin, albumin, creatinine, alanine aminotransferase, white blood 
cells, and estimated glomerular filtration rate vs the natural logarithm of average 
monthly reimbursement (y-axis) for total health care services in 177 chronic kidney 
disease patients over 1 year.
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Figure 2 scatter plot of the linear predictor for average chronic kidney disease 
stage (x-axis) vs the natural logarithm of average monthly reimbursement (y-axis) 
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The subsequent rows in the table display the mean values of 
the natural logarithm for average monthly reimbursements 
in each group, along with standard deviation, minimum, and 
maximum values.
The average monthly reimbursements for all three 
methods to evaluate outcome over the study period were not 
found to demonstrate any significant difference in a one-way 
ANOVA test. The mean value for the natural logarithm of 
reimbursement ranged from a low of 4.00 to a high value 
of 8.65.
As expected due to the lower sensitivity in CKD staging, 
122 patients ended the study year with no change in their 
CKD stage. This result is contrasted to the distribution of 
patients according to ending eGFR and ICS. Separation of 
the pool by ICS demonstrated five patients with an unchanged 
score from start to end, while 60 improved values and 112 
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Figure 3 Line graph for 177 renal patients (x-axis) depicting each patient’s average illness complexity score (red line) along with each patient’s respective natural logarithm for average 
monthly reimbursement (green line). The y-axis represents values for average illness complexity score and the average natural logarithm for total monthly reimbursements.
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Figure 4 Line graph for 177 renal patients (x-axis) with an average chronic kidney disease stage that ended worse than their starting stage. The y-axis represents values for 
average chronic kidney disease stage and the average natural logarithm for total monthly reimbursements for all delivered medical services. Red line is the complexity score 
for each patient, while the green line is the average natural logarithm for total monthly payments made for each patient.International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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had a worse ending ICS. This observation is consistent with 
  clinical experience that CKD patients demonstrate progres-
sive debilitating illness, not only in renal function but in asso-
ciated comorbid conditions. On the other hand, the observed 
eGFR ending values for the three cohorts demonstrated a 
distribution of 50, 64, and 63 patients within the groups of 
same, better, and worse, respectively.
The change from start to end eGFR, ICS, and CKD 
stage in patients with better and worse ending scores were   
evaluated by a paired t-test. Each group demonstrated ending 
values that were significantly different from starting values at 
P value = 0.005. As seen in Table 3, due to the wide range of 
reimbursements seen in each group, an ANOVA calculation 
did not reveal a significant difference in average monthly 
reimbursements between groups.
An objective of this study was to compare the association 
of ICS and CKD stage to reimbursement. Since ICS dem-
onstrated a better relationship to reimbursement, a plot of 
predicted cost vs the ICS linear predictor was calculated. The 
resultant calculation for predicted average monthly dollars is 
shown as the plot of the predicted cost vs ICS in Figure 5.
The x-axis demonstrates the linear predictor for each 
patient and the y-axis is the calculated exponential for each 
patient’s linear predictor in dollars. For linear predictor 
values below 7.0, the average monthly reimbursement for 
these patients is predicted at under US$500. As the predictor 
value increases to 7.5, the predicted reimbursement doubles 
to US$1000 per month. When the predictor reaches a value 
of 8.65 the predicted monthly reimbursement increases to 
nearly US$3000 monthly.
Discussion
As patients, payers, and elected officials seek to improve the 
public health and lower health care costs, there is the need 
to understand the correlation between illness complexity, 
outcome, and reimbursement. Recent legislation to reform 
health care and provide universal coverage mandates a shift 
in provider compensation to a system that rewards value-
based outcomes. Generally, when we consider payment for 
professional services, intuitively we expect cost to parallel 
problem complexity, ie, the more severe the problem, the 
higher the expected cost. Conversely, if the problem is rou-
tine, so is the expected fee. Based on this assumption, the 
goal of this study was to evaluate how routine blood tests 
commonly ordered by family physicians and nephrologists 
are related to predicting cost. Since CKD patients typify 
individuals with a progressive chronic disease, which is 
complicated by multiple comorbid conditions, such patients 
were elected for study to evaluate routine blood chemistry 
profiles that capture indications for liver disease, cardiac 
disease, anemia, infection, and other conditions associated 
with CKD. The next objective was to determine if this addi-
tional information had a relationship to reimbursement, and 
if it provided more sensitivity than analysis of claims data 
and stage of CKD.
In order to accomplish these objectives, a derivative of 
select blood chemistry values was evaluated to develop an 
ICS and determine if that numeric value reliably related to 
reimbursement. Next ICS were examined to determine if it 
offered more information about disease severity than CKD 
staging alone. The results of this study demonstrated that 
Table 3 Values for the number of patients who completed the study period with the same, better, or worse ending egFR, ICs, or 
CKD stage. The remaining rows display the natural logarithm values for mean, minimum, and maximum monthly reimbursement for all 
delivered health care services, along with group standard deviation
Ending e-GFR Ending ICS Ending stage
Same Better Worse Same Better Worse Same Better Worse
n-pts 50 64 63 5 60 112 122 25 30
Mean 5.53 5.70 5.80 5.29 5.64 5.85 5.71 5.95 5.84
sD 1.08 1.03 1.07 1.20 0.92 1.00 0.95 1.16 0.96
Minimum 4.71 4.00 4.07 4.28 4.21 4.00 4.00 4.21 4.59
Maximum 8.21 8.48 8.65 7.35 8.31 8.65 8.50 8.65 8.32
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ICS, illness complexity score; SD, standard deviation; n-pts, number of patients.
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Figure 5 scatter plot of predicted average monthly cost for the illness complexity 
score linear predictor in 177 chronic kidney disease patients. The x-axis demonstrates 
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average ICS values had a reliable association with predicted 
average monthly reimbursements at an R2 value of 0.41. 
When that value was compared to the association between 
average CKD stage and average monthly reimbursement, it 
revealed an R2 value of 0.08. Thus, ICS offered five times 
greater sensitivity over CKD staging as a measure of illness 
complexity.
A major concern for payers, under any system, is that 
providers will revert to a fee-for-service concept, which 
incentivizes the use of more procedures. Without reliable 
objective tools to score illness complexity and outcome, 
both providers and payers must then depend on anecdotal 
arguments to debate disagreements over patient complexity 
and fair reimbursement. The inability to predict expected 
treatment cost in individual patients presents a challenge to 
future accountable care organizations as they develop risk-
adjusted capitation agreements. Although Kidney Disease: 
Outcomes Quality Initiative/Kidney Disease: Improving 
Global Outcomes are expected to imminently release an 
update to CKD staging that employs eGFR and proteinuria/
albuminuria to classify CKD, these authors believe ICS 
scaling, which accounts for additional comorbid conditions, 
can augment the sensitivity of upcoming disease specific 
  classifications. In this manner, payers can evaluate claims 
based on data for individual patients rather than employing 
global categories based on broad classification of disease by 
stage. The comorbidities that occur in CKD patients are as, 
or more, important determinates of illness complexity than 
kidney function. While it is important to develop improved 
measures of kidney function, it is also important to develop an 
illness complexity index that reflects all aspects of complexity 
and not simply the root cause of that complexity.
This study was undertaken to begin a dialog and suggest 
further research in developing a dynamic measuring tool 
that scales illness complexity over the course of treatment 
in CKD patients, while still respecting the concerns of over-
utilization in health care services. Such a tool can augment 
current metrics based on ordinal staging of CKD. The ICS 
discussed in this study is derived from the summation of a 
constant (ie, intercept) and beta-weighted values of patient 
age and select serum chemistry values, which produced a 
single score based for the standardized deviation of blood 
tests from their normal mean. The beta-weights (regression 
coefficients) were calculated from a linear regression of 
average Z-scores for each blood test for each patient in the 
study pool on the natural logarithm of average total monthly 
reimbursements for those same patients. The resultant regres-
sion coefficients were then subsequently used to weight the 
most significant blood test results shown in Table 2 for any 
patient on any single date of service. The final ICS for any 
given date of service was based on these weighted factors. 
With future access to larger data pools, with more longitu-
dinal observations for each variable, the reliability for these 
coefficients are likely to improve.
These authors understand that staging renal disease by 
a calculated eGFR is a gold standard for evaluating patients 
with kidney dysfunction. However, the concern is that deter-
mining payment for health care services based primarily on 
this measure does not illuminate the impact of comorbid 
conditions or account for different outcomes influenced by 
this additional complexity. Though there are many other tests 
which could be employed in a CKD population, this study was 
restricted to those serum chemistry values considered by the 
consulting nephrologists to be important in monitoring CKD 
patients, and importantly were often ordered by primary care 
physicians as part of a routine blood panel.
The development of disease specific severity scales is not 
new. Indeed, an example study by Kriegsman et al described 
how many factors including patient mobility are significantly 
impacted by complications arising from comorbid conditions 
that influence a primary chronic disease.18 Other authors also 
analyzed how different chronic diseases had specific char-
acteristics which explained mobility limitations particularly 
in the elderly.19,20 The impact of arthritis, cardiac disease, 
cerebrovascular disorders, chronic pulmonary disease, and 
diabetes, many of which accompany CKD can significantly 
alter a value-based treatment outcome.
However, many articles which report disease specific 
severity indexes on outcome, base their improvements on 
refinements achieved through better classification of claims 
data such as diagnosis-related groups, International Statistical 
Classification of Diseases and Related Health Problems-9, or 
discharge summary reports.21–24 These authors believe ICS 
based on the association of select blood chemistry values to 
reimbursement adds a level of dynamic objectivity to chang-
ing health status in chronically ill patients, and potentially 
offers synergy to current methods of grading based on stage 
classification.
study limitations
Due to the need for specific and repeated blood chemistry 
tests, this preliminary study of 177 CKD patients was dis-
tilled from a renal registry containing 888 patients. With the 
ever increasing use of electronic health records, along with 
the availability of physical measurements, such as systolic 
blood pressure, body mass index, microalbuminuria, and International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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cardiac function studies, which could be added to the linear 
predictors employed in this study, these authors believe the 
relationship between ICS and reimbursement can be further 
improved.
In dealing with a small data set, the question of compari-
son to a validation data set arises. In addition, since the study 
requirements included the repeated collection of all selected 
blood tests, the test population could be influenced by selection 
bias. These individuals could be sicker, or different in some 
important way from the larger population. These authors believe 
that is not the case in our study since several parameters within 
the test group were compared to the larger population of 888 
CKD patients who had the required blood tests but not on the 
repeated protocol which we required. In regards to age, average 
stage of CKD, and average eGFR, the smaller test group had 
values of 67 years, stage 3.6, and 30.5 mL/minute, while the 
larger group had 68 years, stage 3.6, and 35.2 mL/minute. The 
average Z-scores for serum creatinine and hemoglobin values 
in the smaller test group were 8.1 and -2.3, while the values 
in the larger group were 6.0 and -2.2, respectively. In terms 
of reimbursements, the test group had average monthly costs 
of US$1426 while the larger group had US$1696.
Summary
In summary, it was found that:
•	 An ICS derived as the predicted value of the average 
logarithm of reimbursement from the linear regression 
on patient age and several select serum chemistry values 
in CKD patients produces a single score that significantly 
relates reimbursement to illness complexity (R2 = 0.41, 
P = 0.0005).
•	 Sorting the same patient population by CKD stage and 
relating it through a simple linear regression to the natural 
logarithm of average monthly reimbursement demon-
strated an R2 value of only 0.08. Thus ICS demonstrated 
sensitivity five times greater.
•	 Sorting the patient population by change in CKD stage, 
ICS, and eGFR over the entire study period demonstrated 
significant differences in starting and ending values. 
When the study pool was sorted by CKD stage 122 of 
177 patients ended the period with the same stage as they 
began. On the other hand, sorting of the pool by ICS 
revealed that 112 of 177 patients ended the period with 
worse scores than at start. Sorting of the pool by eGFR 
revealed a nearly even distribution of patients with same, 
better or worse ending eGFRs.
•	 Since ICS demonstrated a better relationship to average 
monthly reimbursement, the exponential linear predictor 
for ICS was plotted as predicted monthly cost for CKD 
patients with increasing illness severity.
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